| Revision as of 16:10, 18 July 2017 editJustlettersandnumbers (talk | contribs)Autopatrolled, Administrators120,844 edits date, tense (reported speech)← Previous edit | Revision as of 16:13, 18 July 2017 edit undoJustlettersandnumbers (talk | contribs)Autopatrolled, Administrators120,844 edits what the source actually saysNext edit → | ||
| Line 10: | Line 10: | ||
| Puliafito received a degree in medicine from ] and completed a ] in ] and a ] in ] at ]. He has an ] from the ] of the ].<ref name=usc/> | Puliafito received a degree in medicine from ] and completed a ] in ] and a ] in ] at ]. He has an ] from the ] of the ].<ref name=usc/> | ||
| He was appointed dean of the ] in December 2007.<ref>USC Press Release. Dec 5 2007. </ref> Before that, he had been director of the ] of the ], and chair of the department of ophthalmology.<ref name=usc>. University of Southern California. Accessed February 2015.{{self-published source|date=February 2015}}</ref> In 2012 he was 21st of the most highly-paid research university executives in the United States.<ref>{{cite news | url=http://www.genengnews.com/keywordsandtools/print/3/33096/ | publisher=Genetic Engineering & Biotechnology News | title=25 Top-Paid Research University Leaders | date=Nov 18, 2013 | author=Alex Philippidis }} Accessed February 2015.</ref> In March 2016, Puliafito resigned as dean of the Keck and USC professor ] was appointed interim dean.<ref name=trojan>{{Cite web|url=http://dailytrojan.com/2016/03/24/dean-keck-school-medicine-usc-resigns/|title=Dean of Keck School of Medicine of USC resigns |last=Maamoon|first=Noorhan|website=Daily Trojan|access-date=2016-04-03}}</ref> | |||
| He has served on the board of the ].<ref>http://www.chla.org/site/c.ipINKTOAJsG/b.5264283/</ref> | He has served on the board of the ].<ref>http://www.chla.org/site/c.ipINKTOAJsG/b.5264283/</ref> | ||
Revision as of 16:13, 18 July 2017
 |
Carmen A. Puliafito is an American ophthalmologist. From 2007 until March 2017 he was dean of the University of Southern California medical school, the Keck School of Medicine.
Career
Puliafito received a degree in medicine from Harvard Medical School and completed a residency in ophthalmology and a fellowship in vitreoretinal surgery at Massachusetts Eye and Ear Infirmary. He has an MBA from the Wharton School of the University of Pennsylvania.
He was appointed dean of the Keck School of Medicine of USC in December 2007. Before that, he had been director of the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine, and chair of the department of ophthalmology. In 2012 he was 21st of the most highly-paid research university executives in the United States. In March 2016, Puliafito resigned as dean of the Keck and USC professor Rohit Varma was appointed interim dean. He has served on the board of the Children's Hospital Los Angeles.
Research
Puliafito was one of the inventors of optical coherence tomography (OCT); for this work, James Fujimoto, Eric Swanson and Puliafito received a Rank Prize for Opto-electronics in 2002. In 2012 Fujimoto, Swanson and David Huang, with Puliafito and Joel Schuman, received an António Champalimaud Vision Award from the Champalimaud Foundation.
Puliafito participated in research into the use of bevacizumab for the treatment of retinal disorders.
2017 Los Angeles Times report
The Los Angeles Times reported in July 2017 that while Pulafito served as dean and USC professor, he "kept company with a circle of criminals and drug users who said he used methamphetamine and other drugs with them." The reporters reviewed video and photographs of Puliafito engaging in these activities in hotel rooms, apartments, and the dean's office. According to the newspaper, a 21-year-old prostitute had overdosed while taking drugs with Puliafito in a Pasadena hotel room on March 4, 2016; the article included a recording of a conversation between a 911 operator and an unidentified man in the hotel room who said he was a doctor. The report said that police had found methamphetamine in the room. Three weeks later, on March 24, Puliafito resigned as dean of the Keck.
References
- ^ Carmen Puliafito named new dean of the Keck School of Medicine. University of Southern California. Accessed February 2015.
- USC Press Release. Dec 5 2007. USC Installs Dr. Carmen Puliafito as New Dean of the Keck School of Medicine
- Alex Philippidis (Nov 18, 2013). "25 Top-Paid Research University Leaders". Genetic Engineering & Biotechnology News. Accessed February 2015.
- ^ Maamoon, Noorhan. "Dean of Keck School of Medicine of USC resigns". Daily Trojan. Retrieved 2016-04-03.
- http://www.chla.org/site/c.ipINKTOAJsG/b.5264283/
- ^ (May 2002). New Products. Optometry & Vision Science 79 (5): 279–280. Accessed February 2015.
- 2012: Williams & Fujimoto, Huang, Puliafito, Schuman, Swanson. Champalimaud Foundation. Accessed February 2015.
- Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. (2005). Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–47.
- Rosenfeld PJ, Moshfegi AA, Puliafito CA. (2005). Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surgery, Lasers & Imaging 36: 331–5.
- Rich RM, Rosenfeld PJ, Puliafito CA, et al. (2006). Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495–511.
- Moshfegi AA, Rosenfeld PJ, Puliafito CA, et al. (2006). Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113: 2002–11.
- ^ Pringle, Paul; Ryan, Harriet; Elmahrek, Adam; Hamilton, Matt; Parvini, Sarah (July 17, 2017). "An overdose, a young companion, drug-fueled parties: The secret life of USC med school dean". Los Angeles Times.